Nuper, Talis biomedical, US-fundatur societatis specialiter in puncto-of-cura infectiosis morbo testis, nuntiatum quod est inceperat explorans opportuna alternatives et erit cutis circa XC% of ejus workforce ad conservare cash.
In a statement, Talis said that the company's Board of Directors has appointed a special committee composed of independent directors to consider various strategic alternatives, including equity or debt financing alternatives, acquisitions, mergers or reverse mergers, asset divestitures, licensing, or other strategic transactions . TD Cowen et serve sicut Financial Advisor in hac recenseo.
In comitatu non posuit a timeline ad completing in opportuna processum et asseruit quod non intendit ad providere updates in progressu, nisi dignatus oportet vel necessarium.
Talis etiam consilia ad redigendum suum workforce per circiter XC% et consolidare sua res in unum locum in Chicago. Praeterea, in comitatu erit effectum deducendi ulterius sumptus-salvis mensuras ad redigendum cash ardere.
Talis nuntiatum suum tertium-quartam financial praecessi, renuntiationes de $ 140.000 ad quartam, deorsum a $ 796,000 anno ante. Dona Vectigal erat $ 64,000 et uber VECTIGALES TESTAGED $ 76,000 ad quartam. Net damnum ad tertiam partem MMXXIII erat $ 15,7 million (circiter RMB CXIII million) comparari ad $ XXVI decies in eodem tempore anni. In comitatu erat $ LXXXVIII decies in cash et equivalents ad extremum quartam.
Postquam erigens $ CCLIV decies in initial initial offering in MMXXI, Talis habet versus seriem incommodis. Last anno, in comitatu Conscidisti XXXV% of ejus workforce et nuntiatum quod esset consistere in commercialization eius Covi-XIX test ad focus in occasiones in mulieribus et sexualem sanitas sectos. In principio MMXXII, debitum ad vestibulum exitibus et inefficiencies major quam X%, Talis nuntiatum quod launch de eius talis unum Mycocular Diagnostics ratio esset moratus. Talis unus ratio utitur realis-vicis loop-mediated isothermal amplificationem (lucerna) technology pro DNA scuta et realis-vicis vicissim transcriptionem lucerna technology pro RNA peltas.
Post tempus: Aug-26-2024